Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening

Size: px
Start display at page:

Download "Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening"

Transcription

1 Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening

2 There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention and Control Routine Practices and Additional Precautions in All Health Care Settings November 2012 Appropriate for but not limited to: acute care, long-term care, chronic (including mental health) care and home health care Incorporates Ministry of Health and Long-Term Care. Control of Clostridium difficile Infection (CDI) Outbreaks in Hospitals, A Guide for Hospital and Health Unit Staff

3 Background Mandatory public reporting of nosocomial CDI began in Ontario public hospitals in Sept Between 2009 and 2011, rates of CDI increased 13% in Acute Teaching and Large Community Hospitals (from 0.30/1000 patient days in 2009 to 0.34/1000 patient days in 2011) Current rate as of July 2013 is 0.29/1000 patient days 3

4 Emerging CDI knowledge Data is starting to accumulate regarding communityassociated C. diff Role of community environments, food, water sources and animal sources of C. diff may need to be considered more research is currently underway 4

5 Outbreak investigations Number of strains identified per outbreak ranged from 1 to 41, with a median of 3 distinct strains Is it an outbreak? Is community acquisition/carriage and antibiotic use contributing to the burden and expression of CDI in hospital? NAP1 Strain represented 60% of all C. difficile outbreak strains as tested by PHO laboratories. All isolates were susceptible to metronizadole and vancomycin (still preferred treatment options) 5

6 So what s changed in this Annex? A number of updates including: IPAC measures CDI testing and surveillance (addition to the case definition and removal of 80 th percentile as an outbreak threshold) Management of CDI outbreaks Overall, stronger positions on patient accommodations, enhanced cleaning practices, baseline rate determination, surveillance and treatments 6

7 There are two major components to successful control of CDI effective infection prevention and control (IPAC) measures and antibiotic stewardship Annex C, 2013 p.5 7

8 IPAC Measures Sustained control of CDI may be achieved with a bundle of IPAC measures directed at interrupting the horizontal spread A system for identification and prompt isolation of suspected or known CDI cases Appropriate environmental services policies and procedures for rooms/bathrooms of CDI cases, including use of sporicides A hand hygiene program A system for disposal of human waste that prevents environmental contamination Access to appropriate and timely laboratory testing 8

9 Treatment New antibiotic option Fidaxomicin Similar to vancomycin for curing CDI and is superior for reducing CDI recurrences New prevention and treatment modalities that are being explored include; probiotics faecal microbiota transplantation 9

10 Other IPAC measures covered are: Discontinuation of precautions for CDI Relapse of symptoms Occupational Health 10

11 CDI Testing and Surveillance Ideally laboratory testing turnaround should be less than 24 hours and the test should be available 7 days per week Testing by molecular methods (PCR) is more sensitive and is now considered testing method of choice If the first molecular test is negative there is no need for a second test Re-testing for test of cure is not indicated Testing should not be carried out on formed stools 11

12 Case Definition of Clostridium difficile Infection (CDI) Laboratory confirmation of C.difficile together with diarrhea* or Visualization of pseudomembranes on sigmoidoscopy or colonoscopy or Histological/pathological diagnosis of pseudomembranous colitis or Diagnosis of toxic megacolon PLUS (newly added to the case definition) For the purpose of defining a case of CDI, there should be 3 or more episodes of diarrhea within a 24 hour period *Remember to initiate contact precautions at onset of diarrhea without waiting for further episodes 12

13 Case Definition Testing can detect C. difficile colonization or disease Results of laboratory testing must be correlated with the clinical condition of the patient/resident 13

14 CDI Outbreak identification and thresholds Cases of CDI occurring at a rate exceeding the normally expected baseline rate for the health care setting during a specified period of time should be investigated as a possible outbreak CDI outbreak definitions incorporate the concept of notification thresholds points that trigger action and dialogue between local public health unit and the facility 14

15 CDI Notification thresholds: For wards/units with 20 beds, three (3) new cases of nosocomial CDI identified on one ward/unit within a seven-day period OR five (5) new cases of nosocomial CDI within a four-week period, 15

16 CDI Notification Thresholds For wards/units with <20 beds, two (2) new cases of nosocomial CDI identified on one ward/unit within a seven-day period OR four (4) new cases of nosocomial CDI within a four-week period, 16

17 CDI attribution: Yours? Ours? Their s? Annex C provides surveillance guidance and this differs from public reporting requirements, which has three levels of attribution Careful and full review of the case clinical information and past history is needed when determining attribution 17

18 CDI Outbreaks (cont d) Facilities that have a facility nosocomial CDI rate that exceeds their annual nosocomial baseline rate for a period of two consecutive months NOTE: This is not valid for a small community hospital, where a single case of nosocomial CDI can artificially elevate the facility rate 18

19 Note: exceeding a threshold does not necessarily imply that an outbreak will be declared Consultation with local public health unit and/or with the local regional infection control network is available for facilities with limited experience in managing CDI outbreaks 19

20 And now over to Grace Volkening CLEANING UP ON CDI 20

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics

Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection

More information

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)

9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI) Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In

More information

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE

ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual

More information

Indicator Definition

Indicator Definition Hospital Acquired Clostridium difficile Infection (CDI) Rate Full data definition sign-off completed. Name of Measure Name of Measure (short) Domain Type of Measure Business Context Rationale Hospital

More information

A Pharmacist Perspective

A Pharmacist Perspective Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed

More information

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?

Case 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool

More information

Clostridium difficile Infection: Diagnosis and Management

Clostridium difficile Infection: Diagnosis and Management Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,

More information

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick

More information

CDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers

CDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines

More information

Clostridium difficile Infection (CDI) Management Guideline

Clostridium difficile Infection (CDI) Management Guideline Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for

More information

Cohorting in Acute Care Impact on LTC Resident Repatriation During an Outbreak

Cohorting in Acute Care Impact on LTC Resident Repatriation During an Outbreak Cohorting in Acute Care Impact on LTC Resident Repatriation During an Outbreak Gary E Garber MD FRCPC FACP Medical Director- IPAC Public health Ontario Objectives Why talk about cohorting? Cohorting when

More information

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated

More information

A Review of the Epidemiology and Current Issues of Clostridium difficile Infection (CDI) in Ontario

A Review of the Epidemiology and Current Issues of Clostridium difficile Infection (CDI) in Ontario A Review of the Epidemiology and Current Issues of Clostridium difficile Infection (CDI) in Ontario Agnes Tong Dr. Doug Sider PHO Rounds: November 1, 2011. A Review of the Epidemiology of Clostridium difficile

More information

Clostridium difficile Essential information

Clostridium difficile Essential information Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified

More information

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS

HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS SURVEILLANCE REPORT JANUARY 1 st, 2007 TO DECEMBER 31 st, 2012 TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH

More information

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment. C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin

More information

Clostridium difficile Infection (CDI)

Clostridium difficile Infection (CDI) 18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through

More information

March 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments

March 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE

More information

Los Angeles County Department of Public Health: Your Partner in CDI Prevention

Los Angeles County Department of Public Health: Your Partner in CDI Prevention Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov

More information

ABSTRACT PURPOSE METHODS

ABSTRACT PURPOSE METHODS ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection

More information

6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations

6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM

More information

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical

More information

Updates to pharmacological management in the prevention of recurrent Clostridium difficile

Updates to pharmacological management in the prevention of recurrent Clostridium difficile Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing

More information

Clostridium difficile infection surveillance: Applying the case definition

Clostridium difficile infection surveillance: Applying the case definition Clostridium difficile infection surveillance: Applying the case definition PICNet Conference March 3 rd 2016 Presented by: Tara Leigh Donovan, MSc Managing Consultant (Former Epidemiologist) 1 Disclaimer

More information

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013

Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection

More information

Clostridium Difficile Infection in Adults Treatment and Prevention

Clostridium Difficile Infection in Adults Treatment and Prevention Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy

More information

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium

More information

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System

CLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J

More information

Loyola s C diff Journey

Loyola s C diff Journey Loyola s C diff Journey Kevin Smith, MD Associate Chief Medical Officer, Quality & Safety Aziz Ansari, DO Associate Chief Medical Officer, Clinical Optimization/Revenue Integrity Background Loyola Medicine

More information

VIII Congresso Nazionale Maggio 2018

VIII Congresso Nazionale Maggio 2018 VIII Congresso Nazionale Attualità e prospettive nella prevenzione e controllo delle infezioni nelle organizzazioni sanitarie 21-23 Maggio 2018 Bergamo, Ospedale Papa Giovanni XXIII Clostridium difficile

More information

Clostridium Difficile colitismore

Clostridium Difficile colitismore Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis

More information

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click

More information

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which

More information

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal

More information

C. Difficile Testing Protocol

C. Difficile Testing Protocol C. Difficile Testing Protocol Caroline Donovan, RN, BSN, ONC- Infection Control Practitioner Abegail Pangan, RN, MSN, CIC- Infection Control Practitioner U.S. NEWS & WORLD REPORT 2017 2018 RANKINGS Acute

More information

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and

More information

2018 CNISP HAI Surveillance Case definitions

2018 CNISP HAI Surveillance Case definitions 2018 CNISP HAI Surveillance Case definitions The following case definitions for the surveillance of healthcare-associated infections (HAIs) are used by all acute-care hospitals that participate in the

More information

more intense treatments are needed to get rid of the infection.

more intense treatments are needed to get rid of the infection. What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting

More information

Clostridioides difficile Infection: What s the BIG Stink?

Clostridioides difficile Infection: What s the BIG Stink? Clostridioides difficile Infection: What s the BIG Stink? GLORIA MATHIS, RN, BSN, CIC 29 TH ANNUAL MEDICAL SURGICAL CONFERENCE APRIL 4, 2019 SAN FRANCISCO, CA I am sre my patient has C. diff. I cold smell

More information

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011

Clostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast

More information

Protocol for the Scottish Surveillance Programme for Clostridium difficile infection.

Protocol for the Scottish Surveillance Programme for Clostridium difficile infection. National Services Scotland Protocol for the Scottish Surveillance Programme for Clostridium difficile infection. User manual. Version 4.0 Revised January 2017 Health Protection Scotland is a division of

More information

Guidance for obtaining faecal specimens from patients with diarrhoea (Background information)

Guidance for obtaining faecal specimens from patients with diarrhoea (Background information) Guidance for obtaining faecal specimens from patients with diarrhoea (Background information) Version 1.0 Date of Issue: January 2009 Review Date: January 2010 Page 1 of 11 Contents 1. Introduction...

More information

Sponsored by Virox Technologies Inc. C. difficile 101 A brief review of guidelines and controversies

Sponsored by Virox Technologies Inc.   C. difficile 101 A brief review of guidelines and controversies Controlling Clostridium difficile Outbreaks: Going Beyond the Guidelines Michael Gardam Infec

More information

Clinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents

Clinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents Clinical Clostridium Difficile: Standard Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

Modern approach to Clostridium Difficile Infection

Modern approach to Clostridium Difficile Infection Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research

More information

Safe Patient Care Keeping our Residents Safe

Safe Patient Care Keeping our Residents Safe Safe Patient Care Keeping our Residents Safe 2016 Diarrhoea & Vomiting Infection Prevention & Control in Residential Care Setting Patricia Coughlan, Infection Prevention Control Nurse, HSE Disability Services

More information

Update on Clostridium difficile infection.

Update on Clostridium difficile infection. Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible

More information

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS

GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics

More information

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure

Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma

More information

ECHO-Antibiotic Stewardship Program

ECHO-Antibiotic Stewardship Program ECHO-Antibiotic Stewardship Program More Interesting Recent Literature Updates April 20, 2017 Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Antibiotic

More information

ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE

ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE Antimicrobial Resistant Organisms (ARO) Surveillance ANTIMICROBIAL RESISTANT ORGANISMS (ARO) SURVEILLANCE SUMMARY REPORT FOR DATA FROM JANUARY 1, 2009 TO DECEMBER 31, 2013 Updated October 2014 Antimicrobial

More information

Patient Safety Summit 2014

Patient Safety Summit 2014 Patient Safety Summit 2014 The War on C Diff Mark Mellow, MD + C Diff The Organism Gram + bacillus Anaerobic Spore forming Intestinal flora (up to 35% hospitalized patients, 3% of healthy adults) Leading

More information

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.

declara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,

More information

Clostridium difficile: An Overview

Clostridium difficile: An Overview Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section Outline Background Microbiology Burden Pathogenesis Diagnostic testing

More information

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)

Responders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to

More information

Clostridium difficile

Clostridium difficile Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence

More information

Infection Prevention & Control Resources for York Region Long-Term Care Homes

Infection Prevention & Control Resources for York Region Long-Term Care Homes Infection Prevention & Control Resources for York Region Long-Term Care Homes September 2017 CONTENTS INTRODUCTION 1 PUBLIC HEALTH INSPECTIONS 1 POLICY REVIEW 1 OUTBREAK MANAGEMENT 2 EDUCATION AND TRAINING

More information

Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection

Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium

More information

C Difficile - The Ultimate Challenge: Controlling the Spread

C Difficile - The Ultimate Challenge: Controlling the Spread C Difficile - The Ultimate Challenge: Controlling the Spread Linda R. Greene, RN, MPS, CIC Manager of Infection Prevention Highland Hospital Rochester, NY University of Rochester Medical Center linda_greene@urmc.rochester.edu

More information

Infection control in aged care facilities 3 rd February 2019

Infection control in aged care facilities 3 rd February 2019 Infection control in aged care facilities 3 rd February 2019 A/Prof. Paul Griffin FRACP, FRCPA, FACTM, AFACHSM, FIML, MBBS, BSc(Hons) Infectious Diseases Physician and Clinical Microbiologist Director

More information

Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures?

Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures? Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures? Clostridium difficile Clostridium difficile - first described in 1935 when it was isolated

More information

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed

More information

The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM

The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community J Scott Weese DVM DVSc DipACVIM C. difficile Gram positive anaerobic sporeforming bacterium first

More information

Labeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)

Labeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD) Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum

More information

Clostridium difficile Infection (CDI) Guideline

Clostridium difficile Infection (CDI) Guideline Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic

More information

Guidelines on the Prevention, Detection, And Management of Clostridium difficile Infection

Guidelines on the Prevention, Detection, And Management of Clostridium difficile Infection Guidelines on the Prevention, Detection, And Management of Clostridium difficile Infection 1 CLINICAL GUIDELINES CHECKLIST Name of guidelines Guidelines on the Prevention, Detection, and Management of

More information

Corporate Medical Policy Fecal Microbiota Transplantation

Corporate Medical Policy Fecal Microbiota Transplantation Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description

More information

Clostridium difficile infections Crappy Options

Clostridium difficile infections Crappy Options Clostridium difficile infections Crappy Options Alexandru Petre David MD Infectious Diseases April 21, 2015 Objectives Microbiology Epidemiology Who is at risk? Pathogenesis Diagnosis Treatment Historical

More information

HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile

HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile OBJECTIVES HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile Identify and describe the pathophysiology of C. diff. Identify and describe current therapies in treatment of C. diff Identify

More information

Hand Hygiene: Preventing avoidable harm in our care

Hand Hygiene: Preventing avoidable harm in our care Hand Hygiene: Preventing avoidable harm in our care Hand Hygiene Training Presentation for Healthcare Workers in Community and Primary Care National HSE HCAI AMR Clinical Programme 2017 What we will cover

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey

More information

SMT19969: A Selective Therapy for C. difficile Infection

SMT19969: A Selective Therapy for C. difficile Infection SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium

More information

Canadian Nosocomial Infection Surveillance Program

Canadian Nosocomial Infection Surveillance Program Canadian Nosocomial Infection Surveillance Program 2015-2017 Surveillance for Clostridium difficile infection (CDI) Dec 23, 2016 Working Group: Kevin Katz (Chair), Andy Simor, Geoff Taylor, Charles Frenette,

More information

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.

! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011. Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!

More information

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,

More information

The Potential For Microbiome Modification In Critical Illness. Deborah Cook

The Potential For Microbiome Modification In Critical Illness. Deborah Cook The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to

More information

All POOPed out: fecal microbiota transplant in C. difficile

All POOPed out: fecal microbiota transplant in C. difficile All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL

More information

Gastroenteritis Outbreaks Including Norovirus. Module 7

Gastroenteritis Outbreaks Including Norovirus. Module 7 Gastroenteritis Outbreaks Including Norovirus Module 7 Learner Outcomes By the end of this module you will be able to: Outline the case definition for a gastroenteritis outbreak. Explain the difference

More information

Antibiotic treatment comparison in patients with diarrhea

Antibiotic treatment comparison in patients with diarrhea Original Research Article Antibiotic treatment comparison in patients with diarrhea Deva Lal Kast * Senior Consultant Physician, Department of General Medicine, Krishna Hospital, Ex senior Specialist and

More information

Guidance on Prevention and Control of Clostridium difficile Infection (CDI) in health and social care settings in Scotland.

Guidance on Prevention and Control of Clostridium difficile Infection (CDI) in health and social care settings in Scotland. Guidance on Prevention and Control of Clostridium difficile Infection (CDI) in health and social care settings in Scotland. Scottish Health Protection Network Scottish Guidance No 6 2017 edition. September

More information

An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53

An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats

More information

Zinplava. (bezlotoxumab) New Product Slideshow

Zinplava. (bezlotoxumab) New Product Slideshow Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution

More information

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco

Terapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate

More information

Prevention of Healthcare- Associated Gastrointestinal Infections Michael A. Borg and Rodianne Abela

Prevention of Healthcare- Associated Gastrointestinal Infections Michael A. Borg and Rodianne Abela Chapter 19 Prevention of Healthcare- Associated Gastrointestinal Infections Michael A. Borg and Rodianne Abela Key Points Noroviruses are the commonest cause of healthcare-associated gastroenteritis. Isolation

More information

Nursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle

Nursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,

More information

Procedure for the Prevention Control and Management of Clostridium difficile Infection in Care Settings in Shetland

Procedure for the Prevention Control and Management of Clostridium difficile Infection in Care Settings in Shetland Procedure for the Prevention Control and Management of Clostridium difficile Infection in Care Settings in Shetland Adapted from: Model Infection Control Policies (Transmission Based), HPS ICT September

More information

Clinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection

Clinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection Clinical Primer: Position Statement for Fecal Microbiota Transplantation Administration for Recurrent Clostridium difficile Infection Zain Kassam MD, MPH, FRCPC Chief Medical Officer, OpenBiome Disclaimer

More information

Incidence of and risk factors for communityassociated Clostridium difficile infection

Incidence of and risk factors for communityassociated Clostridium difficile infection University of Iowa Iowa Research Online Theses and Dissertations 2010 Incidence of and risk factors for communityassociated Clostridium difficile infection Jennifer Lee Kuntz University of Iowa Copyright

More information

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018

Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile

More information

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of

More information

What s the diff with C. diff.? Accelerating Prevention Using a Bundle Approach

What s the diff with C. diff.? Accelerating Prevention Using a Bundle Approach What s the diff with C. diff.? Accelerating Prevention Using a Bundle Approach GHA Learning & Action Network - 01/13/16 Russ Olmsted Dir., Infection Prevention & Control (IPC) System Office, Livonia olmstedr@trinity-health.org

More information

FECAL TRANSPLANTATION

FECAL TRANSPLANTATION FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome

More information

Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection

Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection Christopher R. Polage, MD, MAS Associate Professor of Pathology and Infectious Diseases UC Davis Disclosures Test materials

More information

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of

More information

REVISION EFFECTIVE DATE N/A

REVISION EFFECTIVE DATE N/A TITLE DISEASE OUTBREAK, EPIDEMIC, OR PANDEMIC DOCUMENT # 1158-01 APPROVAL LEVEL Vice President, Human Resources Vice President, Collaborative Practice, Nursing, and Health Professions Vice President, Quality

More information

Norovirus Outbreak in a Children s Hospital. Jennifer Adams, MT, MPH, CIC April 23, 2015

Norovirus Outbreak in a Children s Hospital. Jennifer Adams, MT, MPH, CIC April 23, 2015 Norovirus Outbreak in a Children s Hospital Jennifer Adams, MT, MPH, CIC April 23, 2015 Objectives Discuss the epidemiology, symptoms, and transmission of norovirus. Identify key infection control activities

More information

ACP Aaron Fieker, D.O

ACP Aaron Fieker, D.O ACP 2016 Aaron Fieker, D.O Colorectal cancer (CRC) Update on screening strategies and tools Irritable Bowel Syndrome (IBS) New therapeutic options C-difficile Updates on treating recurrent disease CRC

More information

Note: Active Table of Contents Click to follow link

Note: Active Table of Contents Click to follow link Clostridium difficile Infection: Prevention, Diagnosis and Treatment Adult/Pediatric Inpatient/Ambulatory/Emergency Department Clinical Practice Guideline Note: Active Table of Contents Click to follow

More information